Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis

医学 内科学 危险分层 病毒 淋巴瘤 病毒学 肿瘤科 癌症研究
作者
Seok Jin Kim,Joon Young Choi,Seung Hyup Hyun,Chang‐Seok Ki,Dongryul Oh,Yong Chan Ahn,Young Hyeh Ko,Sunkyu Choi,Sin‐Ho Jung,Pek‐Lan Khong,Tiffany Tang,Xuexian Yan,Soon Thye Lim,Yok‐Lam Kwong,Won Seog Kim
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:2 (2): e66-e74 被引量:100
标识
DOI:10.1016/s2352-3026(15)00002-2
摘要

Background Assessment of tumour viability after treatment is essential for prediction of treatment failure in patients with extranodal natural killer/T-cell lymphoma (ENKTL). We aimed to assess the use of the post-treatment Deauville score on PET-CT and Epstein-Barr virus DNA as a predictor of residual tumour, to establish the risk of treatment failure in patients with newly diagnosed ENKTL. Methods In a retrospective analysis of patient data we assessed the prognostic relevance of the Deauville score (five-point scale) on PET-CT and circulating Epstein-Barr virus DNA after completion of treatment in consecutive patients with ENKTL who met eligibility criteria (newly diagnosed and received non-anthracycline-based chemotherapy, concurrent chemoradiotherapy, or both together) diagnosed at the Samsung Medical Center in Seoul, South Korea. The primary aim was to assess the association between progression-free survival and risk stratification based on post-treatment Deauville score and Epstein-Barr virus DNA. With an independent cohort from two different hospitals (Hong Kong and Singapore), we validated the prognostic value of our risk model. Findings We included 102 patients diagnosed with ENKTL between Jan 6, 2005, and Nov 18, 2013, in the study cohort, and 38 patients diagnosed with ENKTL between Jan 7, 2009, and June 27, 2013, in the validation cohort. In the study cohort after a median follow-up of 47·2 months (IQR 30·0–65·5), 45 (44%) patients had treatment failure and 33 (32%) had died. Post-treatment Deauville score and Epstein-Barr virus DNA positivity were independently associated with progression-free and overall survival in the multivariable analysis (for post-treatment Deauville score of 3–4, progression-free survival hazard ratio [HR] 3·607, 95% CI 1·772–7·341, univariable p<0·0001; for post-treatment Epstein-Barr virus DNA positivity, progression-free survival HR 3·595, 95% CI 1·598–8·089, univariable p<0·0001). We stratified patients into three groups based on risk of treatment failure: a low-risk group (post-treatment Epstein-Barr virus negativity and post-treatment Deauville score of 1–2), a high-risk group (post-treatment Epstein-Barr virus negativity with a Deauville score 3–4, or post-treatment Epstein-Barr virus positivity with a Deauville score 1–2), and treatment failure (Deauville score of 5 or post-treatment Epstein-Barr positivity with a Deauville of score 3–4). This risk model showed a significant association with progression-free survival (for low risk vs high risk, HR 7·761, 95% CI 2·592–23·233, p<0·0001; for low risk vs failure, HR 18·546, 95% CI 5·997–57·353, p<0·0001). The validation cohort showed the same associations (for low risk vs high risk, HR 22·909, 95% CI 2·850–184·162, p=0·003; for low risk vs failure, HR 50·652, 95% CI 6·114–419·610, p<0·0001). Interpretation Post-treatment Deauville score on PET-CT scan and the presence of Epstein-Barr virus DNA can predict the risk of treatment failure in patients with ENKTL. Our results might be able to help guide clinical practice. Funding Samsung Biomedical Research Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xhl完成签到 ,获得积分10
刚刚
刚刚
刚刚
JiuJiu完成签到,获得积分10
刚刚
刚刚
Josephine完成签到,获得积分20
1秒前
1秒前
Hello的应助被尊敬鸿采纳,获得10
1秒前
1秒前
2秒前
沐风发布了新的文献求助20
2秒前
2秒前
2秒前
2秒前
月半完成签到,获得积分10
2秒前
郝子凯发布了新的文献求助10
3秒前
OK举报风吹麦浪的求助涉嫌违规
3秒前
可爱的函函的应助被JiuJiu采纳,获得10
3秒前
我是老大的应助被追寻思雁采纳,获得10
4秒前
开欣完成签到,获得积分10
4秒前
灵巧的嚣发布了新的文献求助10
4秒前
希望天下0贩的0的应助被羿_liu采纳,获得10
4秒前
精明念瑶完成签到,获得积分10
4秒前
Liyuhong完成签到,获得积分10
5秒前
6秒前
SciGPT的应助被吃个馍馍采纳,获得10
6秒前
6秒前
酷酷的破茧完成签到,获得积分10
7秒前
7秒前
li完成签到,获得积分10
8秒前
Hello的应助被Leo采纳,获得10
8秒前
精明念瑶发布了新的文献求助10
9秒前
9秒前
9秒前
10秒前
10秒前
10秒前
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963